Bamco Inc. NY Cuts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Bamco Inc. NY lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 26.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,500 shares of the company's stock after selling 4,500 shares during the quarter. Bamco Inc. NY's holdings in Zoetis were worth $2,037,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in shares of Zoetis in the 4th quarter valued at about $30,000. Murphy & Mullick Capital Management Corp purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis in the 4th quarter worth about $58,000. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ZTS shares. Stifel Nicolaus reduced their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Piper Sandler raised their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $212.13.

Zoetis Trading Down 1.1 %

NYSE ZTS traded down $1.73 on Friday, reaching $159.96. The company had a trading volume of 4,243,109 shares, compared to its average volume of 2,491,043. The stock has a market cap of $71.37 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock's 50 day moving average is $157.47 and its 200-day moving average is $166.42. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. The business's quarterly revenue was up 1.4% compared to the same quarter last year. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last three months. 0.18% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.